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ORIGINAL ARTICLE
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ABSTRACT
Background and objective: The RENEW trial demon-
strated that bronchoscopic lung volume reduction using
endobronchial coils improves quality of life, pulmonary
function and exercise performance. In this post hoc
analysis of RENEW, we examine the mechanism of
action of endobronchial coils that drives improvement
in clinical outcomes.
Methods: A total of 78 patients from the RENEW coil-
treated group who were treated in one or both lobes
that were deemed as the most destroyed were included
in this retrospective analysis. Expiratory and inspiratory
HRCT scans were used to assess lobar volume change
from baseline to 12 months post coil treatment in
treated and untreated lobes.
Results: Reduction in lobar RV in treated lobes was sig-
nificantly associated with favourable clinical improve-
ment. Independent predictor of the change in RV and
FEV1 was the change in lobar RV reduction in the
treated lobes and for change in 6MWD the absence of
cardiac disease and the change in SGRQ, while the inde-
pendent predictor of change in SGRQ was the change
in 6MWD.
Conclusion: Our results suggest that residual lobar vol-
ume reduction in treated lobes measured by QCT is the
driving mechanism of action of endobronchial coils
leading to positive clinical outcomes. However, the
improvement in exercise capacity and quality of life
seems to be affected by the presence of cardiac disease.
Clinical trial registration: NCT01608490 at ClinicalTrials.gov
Key words: bronchoscopy and interventional techniques,
emphysema, endobronchial coils, lung volume reduction, quan-
titative computed tomographic analysis.
INTRODUCTION
In patients with severe emphysema, severe lung hyper-
inflation impairs breathing mechanics, drastically
diminishing quality of life and exercise tolerance. Cur-
rent lung volume reduction techniques such as lung
volume reduction surgery (LVRS) and endobronchial
valves typically remove or collapse the most diseased
regions to reduce hyperinflation.1 However, broncho-
scopic lung volume reduction using shape-memory
nitinol endobronchial coils is a non-blocking technol-
ogy, in that it allows ventilation of the treated lobe.2
Mechanistically, endobronchial coils are presumed to
be different from either traditional LVRS or
endobronchial valves, although further investigation is
needed to fully elucidate the mechanism of action of
coils. Currently, only small studies have been per-
formed to investigate the coil mechanism of action.3–6
The RENEW trial, an international, multicentre ran-
domized controlled trial, assessed endobronchial coil
treatment in patients with severe lung hyperinflation
and homogeneous or heterogeneous emphysema.7 In
this post hoc analysis of RENEW, our aim was to exam-
ine the mechanism of action of endobronchial coils
that drives improvement in clinical outcomes. We
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SUMMARY AT A GLANCE
Residual lobar volume reduction in treated lobes
measured by QCT was found to be the driving
mechanism of action of endobronchial coils leading
to positive clinical outcomes. However, the
improvement in exercise capacity and quality of life
seems to be affected by the presence of cardiac
disease.
© 2020 The Authors.
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examined computed tomography (CT) scans obtained
from RENEW to measure structural changes from base-




The patients’ characteristics and primary results of the
RENEW trial (NCT01608490) have previously been
reported.7 This was a retrospective analysis in which
we included patients who participated in the RENEW
trial and who were treated with coils bilaterally and
had evaluable inspiratory and expiratory CT scans at
baseline and 12-month follow-up (FU). Furthermore,
patients were excluded when they were treated in one
or both lobes that were not deemed as the most des-
tructed when analysed by quantitative CT (QCT) analy-
sis. As implanting coils in a lobe of lesser ipsilateral
destruction may result in a differing mechanism of
action, these patients were excluded from this mecha-
nistic analysis.8,9 The RENEW trial was approved by all
the 31 trial sites’ medical ethical review committees,
and all patients provided written informed consent.
QCT analysis
After the RENEW 12-month primary endpoint FU visit
and study un-blinding, both baseline and 12-month
HRCT scans for the coil-treated group were analysed
quantitatively (QCT) (Thirona, Nijmegen, The Nether-
lands). The QCT analysis included volumetric and den-
sitometry assessment at a lung and lobar basis.
Percentage heterogeneity was calculated as difference
in %LAA950 between ipsilateral lobes. Lobar volume
change was calculated as the change in lobar volume
from baseline to 12 months post coil treatment for each
of the five lobes, assessed both with expiratory scans
(lobar residual volume (RV) change) and inspiratory
scans (lobar total lung capacity (TLC) change). Lobar
volume change of the treated lobes was defined as the
sum of lobar volume change of both treated lobes.
Lobar volume change of the untreated lobes was
defined as the sum of lobar volume change of the
remaining three untreated lobes. For each lobe, lobar
vital capacity (VC) was calculated as the difference
between lobar RV and lobar TLC. Furthermore,
patients performed 6-min walk test (6MWT),10 lung
function tests (spirometry and body plethysmogra-
phy11,12) and the St George’s Respiratory Questionnaire
(SGRQ)13 at baseline and after 12 months FU.
Statistical analysis
A paired t-test was performed to evaluate the difference
between baseline and 12-month FU in lobar volumes
on CT and other clinical outcomes. Pearson correlation
coefficients were calculated to evaluate the associations
between QCT measured outcomes and clinical
response outcomes. It was also utilized to evaluate the
associations between change in lobar RV and lobar
TLC volumes measured on CT. An independent t-test
was performed to evaluate the difference in change in
clinical outcomes between patients with and without
reduction in lobar RV in treated lobes. A linear multiple
regression analyses (method enter) was performed to
evaluate the independent predictors of change in the
following clinical outcomes: forced expiratory volume
in 1 s (FEV1), RV, 6-min walk distance (6MWD) and
SGRQ total score. To evaluate whether there is a differ-
ence in clinical outcome between two potential mecha-
nisms of action, we performed an independent sample
t-test to evaluate the difference between patients with
and without compensatory expansion of the untreated
lobes. Compensatory expansion of the untreated lobes
was defined as a change in lobar TLC volume in the
untreated lobe of higher than 0 mL. All statistical ana-
lyses were performed using SPSS statistics version
23 (IBM, Armonk, NY, USA). P-values of <0.05 were
considered statistically significant.
RESULTS
Of the 158 patients randomized to the RENEW treat-
ment group, 125 completed bilateral treatment and
had evaluable inspiratory and expiratory HRCT scans
at baseline and 12-month FU. Of these 125 patients,
47 were treated in one or both lobes that were not
deemed as the most destructed when analysed by
QCT.8 In total, 78 patients were included in this analy-
sis and baseline characteristics are shown in Table 1.
The change in lobar volumes measured on CT and
other clinical outcomes are shown in Table 2. Lobar RV
and TLC significantly decreased after 12 months in the
total lung and in treated lobes, while lobar RV and TLC
in the untreated lobes significantly increased. Lobar VC
did not change significantly. Furthermore, statistically
significant clinical improvements were found in RV
(body plethysmography), SGRQ total score and FEV1
but not in 6MWD.
The association between QCT measured outcomes
and clinical response outcomes are shown in Table 3.
The change in lobar RV in the treated lobes was signifi-
cantly associated with favourable clinical improvements
in RV, FEV1 and 6MWD. Change in lobar RV on CT
showed the strongest correlations to clinical outcomes
across all QCT measures analysed.
While Table 3 showed quite strong correlations
between lobar RV reduction in the treated lobes and
RV and FEV1, the correlations to the functional end-
points of 6MWD and SGRQ were weaker or non-
significant (possibly due to the lower number of sub-
jects and hence inadequate power). Furthermore,
patients with reduction in lobar RV in the treated lobes
(>0 mL) significantly improved in RV and FEV1 but not
in SGRQ and 6MWD compared to patients with no
lobar RV reduction in treated lobes (Table S1 in Sup-
plementary Information). We performed a multiple lin-
ear regression model to investigate what drives the
changes in the different clinical endpoints. Table S2
(Supplementary Information) shows that the indepen-
dent predictors of change in 6MWD are the absence of
cardiac disease and the change in SGRQ, while the
independent predictor of change in SGRQ is the
change in 6MWD. The independent predictor of both
© 2020 The Authors.
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the change in RV and FEV1 is the change in lobar RV
reduction in the treated lobes.
Two different mechanisms of action can occur in the
patients with reduction in lobar RV in the coil treated
lobes. One group shows compensatory expansion of
the untreated lobes and one does not show compensa-
tory expansion of the untreated lobes (Table S3
(Supplementary Information), Fig. 1). Except for SGRQ
total score, groups with or without compensatory
expansion did not significantly differ in change in clini-
cal outcomes.
DISCUSSION
Emphysema is characterized by loss of the lung’s natu-
ral elastic recoil, which causes unsupported airways to
collapse during exhalation. This, in turn, causes air
trapping and increased lung volume, which makes
breathing difficult. Endobronchial coils have been
designed to treat this specific pathophysiological chal-
lenge by compressing lung parenchyma, which in turn
creates tissue tension and restores radial support,
thereby tethering airways open to reduce airway col-
lapse and air trapping.2,14,15 This is independent of col-
lateral ventilation. While the design intent of the coils
is well documented, the structural changes resulting
from coil treatment have not previously been quanti-
fied. In this context, the reduction in hyperinflation
measured at a lobar level has never been clearly
demonstrated.
Spirometry and body plethysmography techniques
measure whole lung volumes, while differential effects
in treated versus untreated lobes must be expected
after coil treatment. In a small cohort of 18 patients, it
had been shown for the first time that the lung volume
reduction coil treatment reduces the volume and the
emphysema score at the treated lobes.3 In our analysis
Table 1 Baseline characteristics (n = 78)
Age (years) 62.9  8.1
Male, n (%) 37 (47%)
BMI (kg/m2) 24.9  4.6
BODE index 6.1  1.3
Number of comorbidities, n 2.7  2.1
Four or more comorbidities, n (%) 25 (32%)
% Cardiac comorbidities 30.8 (24)
6MWD (m) 314  76.9
RV (% predicted) 246.8  40.6
RV/TLC (%) 67.1  7.3
FEV1 (% predicted) 25.8  6.4
SGRQ, total score 60.2  13.6
Emphysema distribution†
Heterogeneous, n (%) 22 (28%)
Homogeneous, n (%) 34 (44%)
Mixed, n (%) 22 (28%)
Emphysema (−950 HU) (%) 46.9  12.9
Air trapping (−856 HU) (%) 77.7  10.4
Data are presented as mean  SD or number (%). Cardiac com-
orbidities were based on medical history reported by the investiga-
tor and included current coronary artery disease, congestive heart
failure or atrial fibrillation, but in a stable situation (subjects were
excluded when there was active/symptomatic CAD, CHF
(LVEF < 45% on echocardiogram) or uncontrolled atrial fibrillation).
†Heterogeneous: ≥15% ipsilateral difference in %LAA950 in
both lungs, homogeneous: <15% ipsilateral difference in %
LAA950 in both lungs and mixed: one heterogeneous lung and
one homogeneous lung.
%LAA950, % low-attenuation area < −950 Hounsfield Unit;
6MWD, 6-min walk distance; BMI, body mass index; BODE,
BODE: combined index of B: Body mass index, O: Obstruction
(FEV1), D: Dyspnea (mMRC) and E: exercise (6MWD); CAD, Coro-
nary artery disease; CHF, Congestive heart failure; FEV1, forced
expiratory volume in 1 s; HU, Hounsfield unit; LVEF, left ventric-
ular ejection fraction; RV, residual volume; SGRQ, St George’s
Respiratory Questionnaire; TLC, total lung capacity.
Table 2 Change in lobar volumes on CT and other clinical variables between baseline and 12-month FU (n = 78)
Baseline 12-month FU Difference P-value
Lobar volumes on CT
Change in lobar RV in total lung (mL) 5679  1164 5450  1238 −229  659 0.003
Change in lobar RV in treated lobes (mL) 2899  688 2563  735 −337  467 <0.001
Change in lobar RV in untreated lobes (mL) 2780  708 2888  758 108  409 0.022
Change in lobar TLC in total lung (mL) 7018  1230 6850  1223 −168  427 0.001
Change in lobar TLC in treated lobes (mL) 3449  730 3189  767 −259  354 <0.001
Change in lobar TLC in untreated lobes (mL) 3569  761 3660  797 92  372 0.033
Change in lobar VC in total lung (mL) 1339  622 1399  716 61  686 0.437
Change in lobar VC in treated lobes (mL) 549  275 627  343 77  360 0.62
Change in lobar VC in untreated lobes (mL) 789  406 773  503 −17  441 0.741
Change in clinical variables
Change in RV, body box (mL) 5282  1075 4844  1202 437  897 <0.001
Change in 6MWD (m) 314  77 322  105 7.5  74 0.376
Change in SGRQ, total score 60.2  13.6 51.1  16.2 −9.1  12.9 <0.001
Change in FEV1 (mL) 709  190 770  231 60.4  152 0.001
Data are presented as mean  SD. Paired t-test was performed to evaluate the difference between baseline and 12-month
FU. Significant P-values are depicted in bold.
6MWD, 6-min walk distance; CT, computed tomography; FEV1, forced expiratory volume in 1 s; FU, follow-up; RV, residual volume;
SGRQ, St George’s Respiratory Questionnaire; TLC, total lung capacity; VC, vital capacity.
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of 78 RENEW patients, we confirm that coils signifi-
cantly reduce lobar RV in the treated lobes, and this is
strongly correlated with changes in lung function.
Thus, lobar RV reduction in the treated lobes could be
an important structural change driving clinical
improvements.
However, in contrast to lung function parameters,
the change in lobar RV reduction in the treated lobes
was less significantly associated with a change in exer-
cise capacity or quality of life. The RENEW primary
analysis already showed that comorbidities substan-
tially influence the patient’s improvement in 6MWT
and SGRQ.7 In line, our results show that the indepen-
dent predictors of improvement in 6MWD are the
absence of cardiac disease and the change in quality of
life. Furthermore, the independent predictor of an
improvement in quality of life was the change in
6MWD. Therefore, it seems that the improvement in
exercise capacity and quality of life is not driven by the
change in lobar RV reduction, but is dependent of the
presence or absence of cardiac disease and the change
in quality of life or exercise capacity (Fig. 2). However,
as the reduction in lung volume is less compared with,
for example, LVRS or the treatment with endobronchial
valves, it could also be that this leads to a less signifi-
cant association between the change in lung volume
and exercise capacity and quality of life and that car-
diac comorbidities have more impact. More profound
lung volume reduction has shown a positive effect on
cardiac function,16,17 which could mitigate the impact
of cardiac comorbidities on the change in exercise
capacity. Endobronchial valves have shown a substan-
tial reduction in lobar TLC due to the induced full
lobar collapse18 and volume changes on inspiratory CT
scans post-treatment are used to establish treatment
effectiveness.19,20 It also seems that the targeted lung
volume reduction for valves is much larger when com-
pared to coils, also indicating a different mechanism of



























































































































































































































































































































































































































































































































































































































































































































































































































Figure 1 Scatterplot of change in TLC in treated lobes and
change in RV in treated lobes, divided by difference in groups
with different mechanisms of action and non-responders. ,
Responders without compensatory expansion; , responders
with compensatory expansion; , non-responders (no change in
lobar RV). CT, computed tomography; RV, residual volume; TLC,
total lung capacity.
© 2020 The Authors.
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lobar TLC, our results show that endobronchial coils
instead show a reduction in lobar RV accompanied by
a modest reduction in lobar TLC. We divided our
patients with a reduction in lobar RV into two groups:
one group with a mild compensatory expansion of the
untreated lobes was observed and one group without
any compensatory expansion, as these could be differ-
ent mechanisms of action. These groups could repre-
sent two different mechanisms of action of the coil
treatment (Fig. 1): (i) restoration of elastic recoil and
(ii) classic lung volume reduction. The first potential
mechanism of action includes patients without com-
pensatory expansion of untreated lobes. In these
patients, the RV reduces and TLC does not and there-
fore VC increases. Therefore, the change in clinical
benefit could be caused by decrease in air trapping in
treated and/or untreated lobes which could increase
the elastic recoil. The second potential mechanism of
action includes the patients with compensatory expan-
sion. In these patients, both RV and TLC of the treated
lobe are reduced which can be classified as ‘classic
lobe volume reduction’. With the coil treatment, this
could be caused by compression of the tissue but also
by reactive changes like the so called ‘coil-associated
opacity’. The RENEW study showed that patients with
coil-associated opacities or pneumonia showed supe-
rior improvement in comparison with patient without.7
Figure 3 shows an example of these mechanisms of
action of the coil treatment in a patient.
Clinical outcomes significantly improved in both the
groups with or without compensatory expansion. There
was no significant difference between the groups
suggesting that neither mechanism is superior to the other,
although there was an unexplained significant improve-
ment in SGRQ in the group with compensatory expansion.
SGRQ also significantly improved in patients without
lobar RV reduction in the treated lobes so could be
caused by a placebo effect.
Due to the retrospective design, this study has some
limitations which could have influenced the results. As
the RENEW study was not designed to answer this spe-
cific question, the study might be underpowered and a
prospective study with a larger sample size needs to be
performed to confirm these results. Furthermore, we
Figure 3 Example of mechanism of action of the endobronchial coil treatment in a patient. (A) Pre-treatment X-ray, (B) just post treat-
ment showing coils in position in the right upper lobe, (C) 6 weeks post right upper lobe treatment showing additional visible volume
reduction of this lobe, (D) just post-treatment left upper lobe, (E) 6 weeks post left upper lobe treatment also showing additional visible
volume reduction of this lobe. Below the images, the baseline and follow-up efficacy parameters are given for this patient. All pre- and
post-treatment pressure–volume curves are given at the end, showing a much more efficient expiratory loop. 6MWD, 6-min walk dis-
tance; FEV1, forced expiratory volume in 1 s; RV, residual volume; TLC, total lung capacity.
Figure 2 Scheme of potential mechanism of action of the coil treatment and effect on clinical outcomes. CT, computed tomography;
FEV1, forced expiratory volume in 1 s; RV, residual volume.
Respirology (2020) © 2020 The Authors.
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excluded patients who were treated in an incorrect
lobe, due to the fact that this analysis was focused on
mechanism of action. However, this could have led to
a selection bias.
In conclusion, our results suggest that residual lobar
volume reduction in treated lobes measured by QCT is
potentially the most important mechanism of action of
endobronchial coils leading to positive clinical out-
comes. However, the improvement in exercise capacity
and quality of life seems to be affected by the presence
of concurrent cardiac disease. Furthermore, we investi-
gated two potential different mechanisms of action:
residual lobar volume reduction with compensatory
expansion of the untreated lobes and without compen-
satory expansion. Both mechanisms resulted in clinical
improvements and were equally effective.
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